BMY · News · 20260805N

Acquisition / Partnership / Divestiture

BRISTOL MYERS SQUIBB CO · 2026-08-05 · Importance 71 · Surprise 60

Bristol Myers Squibb was reported to have held early-stage merger discussions with AstraZeneca for a potential combination valued at approximately $400 billion. The proposed transaction would combine major oncology, immunology, hematology, and neuroscience portfolios and could help BMS address anticipated patent expirations for Eliquis and Opdivo by 2028. Reuters and other reports subsequently cited a senior source denying that discussions ever occurred; analysts noted potential antitrust scrutiny, particularly from the U.S. Federal Trade Commission, because of overlapping oncology and immunotherapy products.

Key facts

• A senior source close to the matter stated that there are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb regarding a potential merger. source
• Reuters reported that there are no ongoing discussions between AstraZeneca and Bristol Myers Squibb regarding a potential merger, contradicting an earlier Financial Times report. source
• After a report that there are no ongoing discussions with AstraZeneca, Bristol-Myers Squibb's stock fell 1.4% in premarket trading while AstraZeneca's shares rose by 5.6%. source